Haemonetics (NYSE: HAE) CFO granted 29,312 RSUs with tax withholding

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Haemonetics Corporation EVP and CFO James DArecca reported a new equity compensation grant. He received 29,312 shares of common stock in the form of restricted stock units (RSUs) at no cash cost, increasing his direct equity-based position.

In a related transaction, 2,505 shares were withheld at a market price of $56.29 per share to cover tax obligations tied to RSU vesting, which is not an open-market sale. After these transactions, he directly holds 25,132 shares, a figure that includes previously reported unvested RSUs.

The RSU award was granted under Haemonetics’ Amended and Restated 2019 Long-Term Incentive Compensation Plan. The units vest in three annual installments, with 40% vesting on each of the first two anniversaries of the grant date and the remaining 20% vesting on the third anniversary. Each RSU converts into one share of common stock upon vesting.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DArecca James

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,505	$56.29	$141K
Grant/Award	Common Stock	29,312	$0.00	--

Holdings After Transaction: Common Stock — 25,132 shares (Direct, null)

Footnotes (1)

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSU award size: 29,312 RSUs Shares withheld for taxes: 2,505 shares Tax withholding price: $56.29 per share +4 more

7 metrics

RSU award size 29,312 RSUs Equity grant to CFO James DArecca

Shares withheld for taxes 2,505 shares Tax obligations on RSU vesting

Tax withholding price $56.29 per share Value of shares withheld for tax payments

Post-transaction holdings 25,132 shares Direct holdings after reported transactions, including unvested RSUs

First vesting tranche 40% of RSUs Vests on first anniversary of grant

Second vesting tranche 40% of RSUs Vests on second anniversary of grant

Final vesting tranche 20% of RSUs Vests on third anniversary of grant

Key Terms

restricted stock units ("RSUs"), tax obligations, Long-Term Incentive Compensation Plan, vest in three annual installments, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax obligations financial

"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"

Long-Term Incentive Compensation Plan financial

"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

vest in three annual installments financial

"The RSUs vest in three annual installments with forty percent of the total award vesting"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"

Form 4 Insider Transactions: What Each Field Means →

05/19/2026 - 05:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DArecca James

(Last)

(First)

(Middle)

125 SUMMER STREET

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		F		2,505⁽¹⁾	D	$56.29	25,132⁽²⁾	D
Common Stock	05/15/2026		A		29,312⁽³⁾	A	⁽⁴⁾	54,444⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported.

3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Haemonetics (HAE) report for CFO James DArecca?

Haemonetics reported that CFO James DArecca received 29,312 restricted stock units (RSUs) as equity compensation. The award was granted at no cash cost and is scheduled to vest over three years under the company’s long-term incentive plan.

How many Haemonetics (HAE) shares were withheld for taxes in the CFO’s Form 4?

A total of 2,505 Haemonetics shares were withheld at $56.29 per share to cover tax obligations on vested RSUs. This withholding is recorded as a disposition but is not an open-market sale of stock by the CFO.

What is CFO James DArecca’s reported Haemonetics (HAE) shareholding after these transactions?

Following the reported Form 4 transactions, James DArecca directly holds 25,132 Haemonetics common shares. This reported figure includes previously disclosed unvested RSUs, reflecting both vested and unvested equity positions associated with his compensation.

How do the new RSUs for Haemonetics (HAE) CFO vest over time?

The RSUs granted to the Haemonetics CFO vest in three annual tranches: 40% of the award on the first anniversary of grant, another 40% on the second anniversary, and the remaining 20% on the third anniversary, subject to continued service.

What does each RSU granted to the Haemonetics (HAE) CFO represent?

Each RSU granted to the Haemonetics CFO represents a contingent right to receive one share of the company’s common stock upon vesting. No cash is paid for the RSUs when granted; value is realized as the units vest into shares.

Under which plan were the Haemonetics (HAE) RSUs to the CFO awarded?

The RSUs awarded to the CFO were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. This plan governs equity-based awards intended to align executive compensation with company performance over time.